Janus Henderson Group PLC Has $866.10 Million Position in Ascendis Pharma A/S $ASND

Janus Henderson Group PLC cut its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 6.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,061,641 shares of the biotechnology company’s stock after selling 261,418 shares during the quarter. Janus Henderson Group PLC owned approximately 6.55% of Ascendis Pharma A/S worth $866,104,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Advisory Services Network LLC acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $26,000. Arax Advisory Partners lifted its stake in shares of Ascendis Pharma A/S by 212.2% in the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 104 shares during the period. Leonteq Securities AG acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at about $36,000. Jones Financial Companies Lllp lifted its stake in shares of Ascendis Pharma A/S by 57.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 83 shares during the period. Finally, Global Retirement Partners LLC lifted its stake in shares of Ascendis Pharma A/S by 111.9% in the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 113 shares during the period.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $231.15 on Thursday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. The stock has a 50 day moving average price of $232.16 and a two-hundred day moving average price of $224.09. The firm has a market capitalization of $14.42 billion, a P/E ratio of 26.66 and a beta of 0.39. Ascendis Pharma A/S has a 52 week low of $160.86 and a 52 week high of $250.74.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The company had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million. Equities analysts forecast that Ascendis Pharma A/S will post 14.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ASND shares. Wedbush reaffirmed an “outperform” rating and issued a $273.00 target price on shares of Ascendis Pharma A/S in a research report on Thursday, April 9th. Oppenheimer reaffirmed an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Tuesday, June 9th. Bank of America boosted their target price on Ascendis Pharma A/S from $262.00 to $292.00 and gave the company a “buy” rating in a research report on Thursday, April 16th. Barclays boosted their target price on Ascendis Pharma A/S from $342.00 to $345.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Finally, Stifel Nicolaus set a $332.00 target price on Ascendis Pharma A/S in a research report on Wednesday, March 4th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $295.39.

Insider Buying and Selling

In related news, Director Jean Jacques Bienaime acquired 400 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was purchased at an average cost of $237.80 per share, with a total value of $95,120.00. Following the acquisition, the director owned 400 shares of the company’s stock, valued at approximately $95,120. This trade represents a ? increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. The disclosure for this sale is available in the SEC filing. Insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.